Last updated on April 2019

Patient-reported Outcomes in Vericiguat-treated Patients With HFpEF


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Chronic Heart Failure With Preserved Ejection Fraction
  • Age: Between 45 - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Previous diagnosis of chronic heart failure (HF)
  • HF decompensation within 6 months prior to randomization, defined as hospitalization for HF or intravenous (IV) diuretic treatment for HF without hospitalization.
  • N-terminal pro brain natriuretic peptide (NT-proBNP) 300 or brain natriuretic peptide (BNP) 100 pg/mL in sinus rhythm, or NT-proBNP

600 or BNP 200 pg/mL in atrial fibrillation within 30 days prior to randomization

  • Diagnostic criteria of HFpEF by echocardiography assessed within 12 months prior to randomization (most recent measurement must be used to determine eligibility with no interim event signaling potential deterioration in ejection fraction)
  • Left ventricular ejection fraction (LVEF) 45% and
  • Structural changes indicated by at least one of the following parameters:
  • Left ventricle (LV) hypertrophy (any of the following: intraventricular septal or posterior wall thickness 1.1 cm, and/or LV mass index 115 g/m2 in male and 95 g/m2 in female), or
  • Left atrium (LA) enlargement (any of the following: left atrial volume (LAV) index 29 ml/m2, or LAV >58 mL in male and >52 mL in female patients, or LA area >20 cm2, or LA diameter >40 mm in male and >38 mm in female patients)
  • NYHA class II or III at randomization

Exclusion Criteria:

  • Clinical instability at randomization, defined by
  • Any IV treatment within 24h prior to randomization, and/or
  • SBP 160 mmHg
  • SBP <110 mmHg and/or DBP <40 mmHg and/or symptomatic hypotension
  • Resting heart rate (HR) <50 or 100 beats per minute (bpm)
  • Use of IV inotropes at any time between qualifying HF event and randomization
  • Previous diagnosis of reduced ejection fraction (EF) (EF <40%)
  • Hypertrophic obstructive cardiomyopathy, acute myocarditis, amyloidosis, sarcoidosis, or pericardial disease
  • Primary valvular heart disease requiring surgery or intervention, or within 3 months after valvular surgery or intervention, or active endocarditis
  • Acute coronary syndrome, including unstable angina, Non ST-elevation myocardial infarction or ST-elevation myocardial infarction, or Coronary artery bypass grafting (CABG) within 60 days prior to randomization, or indication for Percutaneous coronary intervention or CABG at the time of randomization
  • Symptomatic carotid stenosis, or transient ischemic attack or stroke within 60 days prior to randomization
  • Complex congenital heart disease
  • Non-cardiac comorbidity (any of the following)
  • Estimated glomerular filtration rate (eGFR) <30 ml/min/1.73 m*2 calculated by Modification of Diet in Renal Disease formula
  • Hepatic insufficiency classified as Child-Pugh B or C
  • Morbid obesity with a body mass index >45 kg/m*2
  • Malignancy or other non-cardiac condition limiting life expectancy to <1 year, per physician judgment
  • Requires continuous home oxygen for severe pulmonary disease or has interstitial lung disease
  • Patients with allergies, intolerance or hypersensitivity to investigational drug or any of the excipients
  • Concurrent or anticipated use of nitrates or NO donors, phosphodiesterase type V (PDE5) inhibitors, or a Soluble guanylate cyclase (sGC) stimulator

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.